RBX2660 clinical trials
Also written RBX2660.
How each study uses RBX2660 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Rebiotix Inc. (5) · Ferring Pharmaceuticals (2) · McMaster Children's Hospital (1)
Studies
Open first, then newest update. How each study uses RBX2660 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile InfectionCompletedPhase 3Ferring PharmaceuticalsNCT05831189Written as RBX2660
- A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative ColitisWithdrawnPhase 1Ferring PharmaceuticalsNCT06260267Written as Microbiota suspension
- Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)CompletedPhase 3Rebiotix Inc.NCT03931941Written as RBX2660
- Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)CompletedPhase 3Rebiotix Inc.NCT03244644Written as RBX2660
- PediCRaFT: Pediatric Crohn's Disease Fecal Transplant TrialCompletedPhase 1McMaster Children's HospitalNCT03378167Written as MICROBIOTA
- Microbiota Restoration Therapy for Recurrent Clostridium Difficile InfectionCompletedPhase 2Rebiotix Inc.NCT02589847Written as RBX2660
- Microbiota Restoration Therapy for Recurrent Clostridium Difficile InfectionCompletedPhase 2Rebiotix Inc.NCT02299570Written as RBX2660 (microbiota suspension)
- Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated DiarrheaCompletedPhase 2Rebiotix Inc.NCT01925417Written as RBX2660 (microbiota suspension)